2-amino 1

1. A compound of the following Formula II:

wherein:

R 2 and R 2 ′ are independently selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyC 2-4 alkylenyl, and alkoxyC 2-4 alkylenyl;

R A1 and R B1 taken together form a fused benzene ring wherein the benzene ring is unsubstituted or substituted by one R 3 group, or substituted by one R 3 group and one R group, or substituted by one or more R groups;

or R A1 and R B1 taken together form a fused 5 to 7 membered saturated, carbocyclic ring wherein the ring is unsubstituted or substituted by one or more R groups;

R is selected from the group consisting of halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and —N(R 9 ) 2 ;

R 1 is selected from the group consisting of:

hydrogen, alkyl, arylalkylenyl, hydroxyalkyl, dihydroxyalkyl, haloalkyl,

—X 1 —Y 1 —R 4 ′,

—X 1 —Y 1 —X 1 ′—Y 1 ′—R 4 ′, and

—X 1 —R 5 ′;

X 1 is alkylene;

X 1 ′ is C 1-4 alkylene or phenylene;

Y 1 is —N(R 8 )—C(O)—, —N(R 8 )—S(O) 2 —, —N(R 8 )—C(R 6 )—N(R 8 )—, —N(R 8 )—C(R 6 )—N(R 8 )—C(O)—, or —N(R 8 )—C(R 6 )—O—;

Y 1 ′ is —S—, —NHC(O)—, —C(O)—O—, or —C(O)—;

R 4 ′ is alkyl, aryl, heteroaryl, heterocyclyl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, heterocyclyl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, dialkylamino, and, in the case of alkyl or heterocyclyl, oxo;

R 5 ′ is

R 3 is

—Z—R 4 ,

Z is selected from the group consisting of a bond and —O—;

R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, and —N(R 4 )—;

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;

R 6 is selected from the group consisting of ═O and ═S;

R 8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; and

R 9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of the following Formula IV:

wherein:

R 2 and R 2 ′ are independently selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyC 2-4 alkylenyl, and alkoxyC 2-4 alkylenyl;

R is selected from the group consisting of halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and —N(R 9 ) 2 ;

R 1 is selected from the group consisting of:

hydrogen, alkyl, arylalkylenyl, hydroxyalkyl, dihydroxyalkyl, haloalkyl,

—X 1 —Y 1 —R 4 ′,

—X 1 —Y 1 —X 1 ′—Y 1 ′—R 4 ′, and

—X 1 —R 5 ′;

X 1 is alkylene;

X 1 ′ is C 1-4 alkylene or phenylene;

Y 1 is —N(R 8 )—C(O)—, —N(R 8 )—S(O) 2 —, —N(R 8 )—C(R 6 )—N(R 8 )—, —N(R 8 )—C(R 6 )—N(R 8 )—C(O)—, or —N(R 8 )—C(R 6 )—O—;

Y 1 ′ is —S—, —NHC(O)—, —C(O)—O—, or —C(O)—;

R 4 ′ is alkyl, aryl, heteroaryl, heterocyclyl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, heterocyclyl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, dialkylamino, and, in the case of alkyl or heterocyclyl, oxo;

R 5 ′ is

R 3 is

—Z—R 4 ,

Z is selected from the group consisting of a bond and —O—;

R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, and —N(R 4 )—;

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7;

n is an integer from 0 to 4;

m is 0 or 1, with the proviso that when m is 1, n is 0 or 1;

R 6 is selected from the group consisting of ═O and ═S;

R 8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; and

R 9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

3. The compound or salt of claim 2 wherein m is 0, and n is 0.

4. The compound or salt of claim 1 wherein R 1 is hydrogen.

5. The compound or salt of claim 1 wherein R 1 is selected from the group consisting of alkyl, hydroxyalkyl, dihydroxyalkyl, haloalkyl, —X 1 —Y 1 —R 4 ′, and —X 1 —R 5 ′; wherein X 1 is alkylene, Y 1 is —N(R 8 )—C(O)—, —N(R 8 )—S(O) 2 —, —N(R 8 )—C(R 6 )—N(R 8 )—, or —N(R 8 )—C(R 6 )—O—; R 4 is alkyl, aryl, heteroaryl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino; and R 5 is

6. The compound or salt of claim 5 wherein R 1 is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, 4-[(methylsulfonyl)amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 3-(acetylamino)propyl, 4-(acetylamino)butyl, 4-[(morpholin-4-ylcarbonyl)amino]butyl, 3-(isobutyrylamino)propyl, 2-[(cyclohexylcarbonyl)amino]-2-methylpropyl, and (1-hydroxycyclobutyl)methyl.

7. The compound or salt of claim 1 wherein R 2 is hydrogen and R 2 ′ is selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 alkoxyC 2-4 alkylenyl, and hydroxyC 2-4 alkylenyl.

8. The compound or salt of claim 7 wherein R 2 is hydrogen, and R 2 ′ is hydrogen.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

10. A method of inducing biosynthesis of at least one of interferon-alpha or tumor necrosis factor-alpha in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

11. The compound or salt of claim 2 wherein R 1 is hydrogen.

12. The compound or salt of claim 2 wherein R 1 is selected from the group consisting of alkyl, hydroxyalkyl, dihydroxyalkyl, haloalkyl, —X 1 —Y 1 —R 4 ′, and —X 1 —R 5 ′; wherein X 1 is alkylene, Y 1 is —N(R 8 )—C(O)—, —N(R 8 )—S(O) 2 —, —N(R 8 )—C(R 6 )—N(R 8 )—, or —N(R 8 )—C(R 6 )—O—; R 4 is alkyl, aryl, heteroaryl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino; and R 5 is

13. The compound or salt of claim 12 wherein R 1 is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, 4-[(methylsulfonyl)amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 3-(acetylamino)propyl, 4-(acetylamino)butyl, 4-[(morpholin-4-ylcarbonyl)amino]butyl, 3-(isobutyrylamino)propyl, 2-[(cyclohexylcarbonyl)amino]-2-methylpropyl, and (1-hydroxycyclobutyl)methyl.

14. The compound or salt of claim 2 wherein R 2 is hydrogen and R 2 ′ is selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 alkoxyC 2-4 alkylenyl, and hydroxyC 2-4 alkylenyl.

15. The compound or salt of claim 14 wherein R 2 is hydrogen, and R 2 ′ is hydrogen.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

17. A method of inducing biosynthesis of at least one of interferon-alpha or tumor necrosis factor-alpha in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

18. The compound or salt of claim 1 wherein R 1 is benzyl.

19. The compound or salt of claim 2 wherein R 1 is benzyl.